Mel@PSMA-R12-125I gradually accumulated in the tumor sites during the first 8 h p.i., showing good targeting properties to PCa tumor cells of the PSMA-targeted nanoparticles. This evidence concerns the gene FOLH1 and posterior cortical atrophy.